Navigation Links
Merriman Capital Announces Sponsorship of Radient Pharmaceuticals Corporation on OTCQX

SAN FRANCISCO, June 23, 2011 /PRNewswire/ -- Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (NASDAQ: MERR), today announced that it will serve as the Designated Advisor for Disclosure (DAD) for Radient Pharmaceuticals Corporation (OTCQX: RXPC) as it transitions from trading on the NYSE Amex and begins trading on OTCQX®.


Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring.  After previously trading on NYSE Amex, the Company announced today that it is now trading on the OTC market's highest tier, OTCQX.  

In making this transition, Radient Pharmaceuticals joins a growing list of companies that have chosen to move off a U.S. exchange and onto OTCQX.  In doing so, the Company and its investors will continue to benefit from a compliance-driven, full-service trading platform that is more efficient and cost-effective than a traditional exchange listing.

OTCQX distinguishes the best companies traded over-the-counter (OTC) from more than 9,000 securities traded on the OTCBB and OTC Link that are not required to meet any financial standards or undergo a qualitative review.

Spencer Grimes, Merriman Capital Managing Director, said: "We are very pleased to be partnering with Radient Pharmaceuticals on their transition to OTCQX.  The decision to be quoted on the more cost effective and efficient OTCQX platform is in their shareholders' best interest and will allow management to stay focused on their core business.  I have no doubt that many more companies will be following Radient Pharmaceuticals from an exchange listing to QTCQX."

Radient Pharmaceuticals CEO, Douglas MacLellan, commented: "In moving to OTCQX, we have chosen to continue to deliver liquidity, transparency and an efficient market for our shareholders, while reducing listing costs for our company, freeing up more time and resources to execute on our core business."

About Merriman Capital, Inc.

Merriman Capital, Inc. is a full-service investment banking firm that provides investment banking, sales and trading, and equity research services to corporate and institutional clients and high net worth investors. Merriman Capital, Inc. is a wholly owned subsidiary of Merriman Holdings, Inc., which is listed on the NASDAQ Stock Market and trades under the symbol "MERR."

Merriman specializes in four growth sector industries: Technology, Telecom, Consumer, Media & Internet and CleanTech Infrastructure. For more information, please go to Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC)

About Radient Pharmaceuticals Corporation

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring.  The Company's focus is on the discovery, development, and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or deterrence.  To learn more about our company, products, and potentially life-saving cancer test, visit


The OTCQX marketplace is the premier tier of the U.S. OTC market.  Investor-focused companies use the quality-controlled OTCQX platform to offer investors transparent trading, superior information, and easy access through their regulated U.S. broker-dealers.  The innovative OTCQX platform offers companies and their shareholders a level of marketplace services formerly available only on a U.S. stock exchange.  For more information and to view a full list of OTCQX companies, visit

Note to Investors

This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of the Company. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K/A filed on April 28, 2011. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," " believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-K/A filed on April 28, 2011, together with this press release and the financial information contained herein, are  available on our website, Please click on "Investor Relations."

SOURCE Merriman Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
2. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
3. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
4. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
7. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
8. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
9. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
10. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
11. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
Post Your Comments:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):